NICE Says Eli Lilly’s Breast Cancer Treatment Isn’t Cost-Effective

NICE did not recommend Eli Lilly’s CDK 4/6 inhibitor Verzenio (abemaciclib) for use by the UK’s National Health Service as an endocrine-based therapy for adults with breast cancer.

The drug appeared to work as well as other first treatments for locally advanced or metastatic, hormone receptor-positive, HER2-negative breast cancer, but NICE said it wasn’t cost-effective compared to other treatments that have already been granted approval on NHS.

Eli Lilly has not publicly disclosed the drug’s price.